A patient is on salbutamol and ipratropium but continues to have nocturnal exacerbations of asthma. What is the next step?

Explanation

## Correct Answer: C. Laba plus inhalation steroids This patient is experiencing nocturnal asthma exacerbations despite being on a short-acting beta-2 agonist (salbutamol) and an anticholinergic (ipratropium). This clinical presentation indicates **inadequately controlled persistent asthma** requiring step-up therapy according to GINA and Indian asthma guidelines. The patient has moved beyond the "reliever-only" or "mild intermittent" category into at least mild-to-moderate persistent asthma. The gold standard step-up from reliever therapy is the addition of an **inhaled corticosteroid (ICS)** combined with a **long-acting beta-2 agonist (LABA)**. This combination addresses both the inflammatory (ICS) and bronchospasm (LABA) components of persistent asthma. LABA monotherapy is contraindicated and must always be paired with ICS due to increased mortality risk. The ICS-LABA combination provides superior nocturnal symptom control and reduces exacerbation frequency compared to increasing doses of short-acting agents. In Indian clinical practice, formulations like fluticasone-salmeterol or budesonide-formoterol are widely available and recommended as first-line step-up therapy for persistent asthma. This approach aligns with GINA Step 3 therapy and is the evidence-based, guideline-concordant choice. ## Why the other options are wrong **A. Oral corticosteroids** — Oral corticosteroids are reserved for acute exacerbations or severe uncontrolled asthma requiring hospitalization, not for step-up maintenance therapy in a patient with nocturnal symptoms. Chronic oral corticosteroids carry significant systemic side effects (osteoporosis, immunosuppression, hyperglycemia) and are avoided as maintenance therapy. ICS inhalation is the preferred anti-inflammatory approach for persistent asthma. **B. Increase the dose of salbutamol** — Increasing a short-acting beta-2 agonist dose addresses only acute bronchospasm, not the underlying inflammation driving nocturnal exacerbations. This is a symptomatic approach that masks disease progression. Escalating SABA use without adding controller therapy (ICS) is ineffective for persistent asthma and does not prevent exacerbations or improve long-term control. **D. Montelukast** — Montelukast (a leukotriene receptor antagonist) is a controller agent but is significantly less effective than ICS-LABA combination for persistent asthma. It is typically reserved as add-on therapy in specific phenotypes (allergic asthma, aspirin-exacerbated asthma) or as an alternative in patients unable to tolerate ICS. It is not the first-line step-up choice for inadequately controlled persistent asthma. ## High-Yield Facts - **ICS-LABA combination** is the gold-standard step-up therapy for persistent asthma inadequately controlled on reliever therapy alone (GINA Step 3). - **LABA monotherapy is contraindicated** — LABAs must always be paired with ICS due to increased risk of asthma-related mortality. - **Nocturnal exacerbations** indicate inadequate disease control and require addition of a controller agent (ICS), not escalation of reliever therapy. - **Inhaled corticosteroids** are the most effective anti-inflammatory agents for asthma and are preferred over oral corticosteroids for maintenance therapy due to minimal systemic absorption. - **ICS-LABA combinations** (fluticasone-salmeterol, budesonide-formoterol) provide superior control of both daytime and nocturnal symptoms compared to monotherapy or SABA escalation. ## Mnemonics **GINA Step-Up Ladder** Step 1: SABA PRN → Step 2: ICS low-dose → Step 3: **ICS-LABA** → Step 4: ICS-LABA high-dose → Step 5: Add biologic. Use when deciding asthma escalation therapy. **LABA Rule** **LABA = Always with ICS** (Never alone). Remember: LABA without ICS = increased mortality. Use whenever LABA is mentioned in asthma management. ## NBE Trap NBE may lure students into choosing oral corticosteroids by framing "exacerbations" as acute events requiring systemic therapy, when the question actually describes chronic inadequate control requiring maintenance controller escalation. The trap is confusing acute exacerbation management with chronic disease step-up. ## Clinical Pearl In Indian outpatient practice, nocturnal asthma is a red flag for inadequate ICS use. Many patients present on SABA alone or SABA + anticholinergic; adding ICS-LABA combination dramatically improves sleep quality and reduces emergency department visits — a practical outcome that resonates with Indian patients managing asthma in resource-limited settings. _Reference: GINA 2023 Global Strategy for Asthma Management and Prevention; KD Tripathi Essentials of Medical Pharmacology Ch. 27 (Bronchodilators and Anti-asthma Drugs)_